image: Figure 1: Putative mechanisms of toxicity. view more
Credit: 2023 Bernstock et al.
“Immunotherapies, including oncolytic virotherapy, connection novel, targeted approaches to dainty encephalon tumors with accrued efficacy and reduced toxicity [5].”
BUFFALO, NY- January 26, 2023 – A caller probe position was published successful Oncotarget's Volume 14 connected January 12, 2023, entitled, “Intraventricular immunovirotherapy; a translational measurement forward.”
In this caller perspective, researchers Joshua D. Bernstock, Sarah Blitz, Kyung-Don Kang, and Gregory K. Friedman from Harvard Medical School, Massachusetts Institute of Technology and University of Alabama astatine Birmingham sermon oncolytic virotherapy with intratumoral engineered type-1 herpes simplex microorganism (HSV). Intraventricular therapy (IVT) has been proven harmless with promising efficacy successful caller objective trials for attraction of some pediatric and big high-grade glioma.
“Oncolytic herpes simplex microorganism type-1 (oHSV) has shown committedness successful objective trials successful some pediatric and big encephalon tumors [6–9].”
However, this attack excludes patients with tumors successful surgically inaccessible and/or eloquent encephalon regions. Current transportation methods are besides incapable to access/treat those patients with metastatic illness successful the spinal cord and/or leptomeningeal disease. A caller preclinical survey has paved the mode for objective translation of intraventricular medication of oHSV by identifying and mitigating the toxicity associated with this way for therapeutic payment successful murine models of disseminated medulloblastoma. This enactment whitethorn yet let for targeting of intractable illness and provides a feasible enactment for the repetitive dosing of clinically applicable immunovirotherapy, G207.
“Overall, demonstrating the information and efficacy of IVT with G207 is simply a important measurement towards expanding the capabilities of oHSV, paving the mode for caller objective trials, and expanding the imaginable of an already promising therapy.”
DOI: https://doi.org/10.18632/oncotarget.28343
Correspondence to: Joshua D. Bernstock, Gregory K. Friedman
Emails: jbernstock@bwh.harvard.edu, gfriedman@uabmc.edu
Keywords: oncolytic virotherapy, herpes simplex microorganism (HSV), G207, intraventricular therapy, leptomeningeal disease
About Oncotarget: Oncotarget (a chiefly oncology-focused, peer-reviewed, unfastened entree journal) aims to maximize probe interaction done insightful peer-review; destruct borders betwixt specialties by linking antithetic fields of oncology, crab probe and biomedical sciences; and foster exertion of basal and objective science.
To larn much astir Oncotarget, sojourn Oncotarget.com and link with america connected societal media:
For media inquiries, please contact: media@impactjournals.com.
Oncotarget Journal Office
6666 East Quaker Str., Suite 1A
Orchard Park, NY 14127
Phone: 1-800-922-0957 (option 2)
###
Method of Research
Commentary/editorial
Subject of Research
Animals
Article Title
Intraventricular immunovirotherapy; a translational measurement forward
Article Publication Date
12-Jan-2023
Disclaimer: AAAS and EurekAlert! are not liable for the accuracy of quality releases posted to EurekAlert! by contributing institutions oregon for the usage of immoderate accusation done the EurekAlert system.
English (US)